BriaCell recently started trading on the TSX Venture Exchange under the symbol BCT, following approval of its qualifying transaction with Capital Pool Company “Ansell Capital Corp”, which has now been delisted. The name change followed a 3.25 to 1 share consolidation. BriaCell is a Los Angeles based breast cancer immunotherapy biotech which has developed a patented whole-cell vaccine, cancer immunotherapy technology called the "BriaVax" vaccine.